Ask My Investor AI
Public company · NYSEPublished company research
TEVA

Identity verified against SEC EDGAR filing 0001193125-26-034532; registered as TEVA PHARMACEUTICAL INDUSTRIES LTD, CIK 0000818686.

Teva Pharmaceutical Industries Limited

Teva's FY2025 filing directly supports a global generics platform that manufactures injectables, specialized sterile products and parenteral dosage forms. It reported $3,657M of US generic-and-biosimilar revenue, $4,044M of Europe generic revenue and $1,721M of International Markets generic revenue. The filing does not isolate sterile or essential-medicine economics, and Q1 2026 global generics declined 16% year over year in local currency. The subject remains NOT_READY.

Ask follow-up research
Reviewed company research · researched 2026-07-29 · not an individual investment recommendation
Listing
public
Ticker
TEVA
Exchange
NYSE
HQ
Israel
Currency
USD
SEC CIK
0000818686
Investment case

How this company captures the theme economics

Competitive position

Teva has broad geographic generic scale and explicitly disclosed sterile, injectable and parenteral capabilities. The reviewed sources do not isolate essential sterile-injectable revenue, capacity, utilization or market share; branded growth also dilutes theme purity.

Scarce assets

Scarce assets in this value chain include validated sterile fill-finish lines and aseptic capacity, lyophilization (freeze-drying) capacity, aseptic quality systems and a clean fda inspection/warning-letter record.

Products, segments, and customers

Teva develops and manufactures generic medicines in multiple dosage forms, including injectables, specialized sterile products and parenteral dosage forms. FY2025 generic revenue was reported separately across the United States, Europe and International Markets.

Theme capture

Direct sterile and injectable capability and broad generic scale are verified. Essential-medicine-specific revenue, hospital exposure, manufacturing capacity and resilience economics are not isolated, while branded products remain central to the issuer's growth strategy.

Conditions

What must be true

  1. Size Teva's sterile-injectable revenue and US hospital exposure; assess how deleveraging constrains capacity investment.
  2. The exposure described for Teva Pharmaceutical Industries must be confirmed as financially material in official filings.

Identifiable catalysts

  • Forthcoming quarterly and annual issuer filings
  • Theme-level catalysts detailed in the Essential medicine manufacturing resilience brief
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Diversified global generics platform (plus branded) with sterile injectable/hospital exposure

Essential medicine manufacturing resilience

Direct sterile, injectable and parenteral capability is verified, alongside $9,422M of FY2025 generic revenue across the United States, Europe and International Markets. The issuer does not isolate essential-medicine or sterile-injectable revenue, so theme-specific exposure cannot be sized.

Evidence
The FY2025 Form 10-K directly supports dosage-form capability and geographic generic revenue. Q1 2026 issuer results add current context: global generics declined 16% year over year in local currency. Neither source supports essential-only economics, capacity utilization, a resilience premium or subject acceptance.
Materiality
not assessed — Geographic generic revenue is disclosed, but sterile-injectable and essential-medicine revenue, orders and margins are not isolated; theme-specific materiality remains unassessed.
Financial evidence

Official SEC filing evidence

Reference period: FY2025.

  • Operating income$2.16 billion
    FY2025[1]
  • Diluted EPS$1.21
    FY2025[1]
  • Operating cash flow$1.65 billion
    FY2025[1]
  • Cash and equivalents$3.56 billion
    FY2025 year-end[1]
  • United States generic and biosimilar revenue$3,657 million
    FY2025[1]
  • Europe generic revenue$4,044 million
    FY2025[1]
  • International Markets generic revenue$1,721 million
    FY2025[1]

Limitation: Filing evidence establishes scale, profitability, cash generation, and leverage. Market-derived valuation is withheld until a licensed market-data feed is connected, and theme materiality is stated separately.

Risks

Material risks and break conditions

Material risks

  • Procurement failure: GPOs and hospitals may keep rewarding lowest price rather than reliability, so validated capacity earns no durable premium (the primary thesis break).
  • GLP-1 concentration: a meaningful share of West and Stevanato growth is GLP-1-driven (~21-22% of Stevanato revenue); destocking or a shift to oral/alternative delivery could reverse it and blur the essential-medicine signal.

Thesis-break conditions

  • FDA/ASHP active sterile-injectable shortage counts fall sustainably toward pre-2020 lows (roughly sub-50 total active shortages) while procurement tenders remain price-only, indicating reliability is not being rewarded.
  • Aggregate sterile fill-finish and containment capacity additions outpace demand, evidenced by falling capacity utilization and softening pricing/mix at West, Stevanato and Gerresheimer over consecutive quarters.
Investability conclusion

Where the evidence lands

The FY2025 filing verifies global generic scale and sterile, injectable and parenteral capability, but not essential-medicine-specific economics, capacity or current valuation. No reviewer has accepted the subject; it remains NOT_READY.

Next diligence

  1. Size Teva's sterile-injectable revenue and US hospital exposure; assess how deleveraging constrains capacity investment.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. TEVA PHARMACEUTICAL INDUSTRIES LTD FY2025 Form 10-KSEC EDGAR · primary · published 2026-02-03 · accessed 2026-07-22
  2. Teva FY2025 resultsTeva Pharmaceutical Industries Limited · primary · published 2026-02-03 · accessed 2026-07-29
  3. Teva Q1 2026 resultsTeva Pharmaceutical Industries Limited · primary · published 2026 · accessed 2026-07-29